ADARx Pharmaceuticals, Inc. SEC filings ADRX
ADARx Pharmaceuticals, Inc. has 47 filings in SEC EDGAR's recent list, going back to Feb 6, 2020. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (unregistered share sale, bylaw or fiscal year change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Sep 28, 2026 | — |
| 424B4 | Prospectus | Sep 28, 2026 | — |
| S-1MEF | Filing | Sep 24, 2026 | — |
| S-1/A | Amended registration statement | Sep 21, 2026 | — |
| S-1/A | Amended registration statement | Sep 14, 2026 | — |
| S-1 | Registration statement | Sep 4, 2026 | — |
Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1802369
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.